Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Diabetes, Obesity & Metabolism|February 22, 2011
Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trialsL A Leiter, D J Betteridge, M Farnier, et al.
The Journal of Cell Biology|December 1, 1996
Transferrin receptor containing the SDYQRL motif of TGN38 causes a reorganization of the recycling compartment but is not targeted to the TGNA O Johnson, R N Ghosh, K W Dunn, et al.
International Journal of Clinical Practice|September 30, 2008
Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension studyD Lütjohann, K von Bergmann, W Sirah, et al.
Diabetes, Obesity & Metabolism|March 18, 2011
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitusC Reasner, L Olansky, T L Seck, et al.
International Journal of Clinical Practice|February 13, 2008
Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE studyJ P D Reckless, P Henry, T Pomykaj, et al.
The Biochemical Journal|February 1, 1976
The purification in high yield and characterization of rat hepatic glucokinaseM J Holroyde, M B Allen, A C Storer, et al.
International Journal of Obesity (2005)|March 10, 2010
A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose studyJ Proietto, A Rissanen, J B Harp, et al.
Transfusion|November 1, 1995
Low incidence of red cell and HLA antibody formation by bone marrow transplant patientsA A Abou-Elella, T A Camarillo, M B Allen, et al.
Diabetes, Obesity & Metabolism|June 4, 2010
A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetesM S Kipnes, P Hollander, K Fujioka, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 1, 2006
Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjectsE M Migoya, A Bergman, D Hreniuk, et al.
Pageof 10